Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice

被引:170
作者
Chen, Z
Sun, JZ
Pradines, A
Favre, G
Adnane, J
Sebti, SM
机构
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program,Dept Biochem & Mol Biol, Tampa, FL 33612 USA
[2] Univ Toulouse 3, UPRES EA 2048, F-31052 Toulouse, France
[3] Ctr Lutte Contre Lanc Claudius Regaud, F-31052 Toulouse, France
关键词
D O I
10.1074/jbc.C000145200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Whereas the GTPase RhoA has been shown to promote proliferation and malignant transformation, the involvement of RhoB in these processes is not well understood. In this manuscript RhoB is shown to be a potent suppressor of transformation and human tumor growth in nude mice. In several human cancer cell lines, RhoA promotes focus formation whereas RhoB is as potent as the tumor suppressor p53 at inhibiting transformation in this assay. RhoB is both farnesylated (F) and geranylgeranylated (GG), and RhoB-F has been suggested as a target for the antitumor activity of farnesyltransferase inhibitors. Here we demonstrate that both RhoB-F and RhoB-GG inhibit anchorage-dependent and -independent growth, induce apoptosis, inhibit constitutive activation of Erk and insulin-like growth factor-1 stimulation of Akt, and suppress tumor growth in nude mice. The data demonstrate that RhoB is a potent suppressor of human tumor growth and that RhoB-F is not a target for farnesyltransferase inhibitors.
引用
收藏
页码:17974 / 17978
页数:5
相关论文
共 19 条
  • [1] RAS GENES
    BARBACID, M
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 : 779 - 827
  • [2] BOS JL, 1989, CANCER RES, V49, P4682
  • [3] Increasing complexity of Ras signaling
    Campbell, SL
    Khosravi-Far, R
    Rossman, KL
    Clark, GJ
    Der, CJ
    [J]. ONCOGENE, 1998, 17 (11) : 1395 - 1413
  • [4] COX AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51
  • [5] THE RAS-RELATED SMALL GTP-BINDING PROTEIN RHOB IS IMMEDIATE-EARLY INDUCIBLE BY DNA-DAMAGING TREATMENTS
    FRITZ, G
    KAINA, B
    AKTORIES, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (42) : 25172 - 25177
  • [6] The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
    Gibbs, JB
    Oliff, A
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 : 143 - 166
  • [7] JAHNER D, 1991, MOL CELL BIOL, V11, P3682
  • [8] KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443
  • [9] Non-Ras targets of farnesyltransferase inhibitors: focus on Rho
    Lebowitz, PF
    Prendergast, GC
    [J]. ONCOGENE, 1998, 17 (11) : 1439 - 1445
  • [10] Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
    Lebowitz, PF
    Casey, PJ
    Prendergast, GC
    Thissen, JA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (25) : 15591 - 15594